Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer and HR+/HER2- Metastatic Breast Cancer

This phase II trial studies the side effects and best dose of ivermectin in combination with balstilimab or pembrolizumab and to see how well they they work in shrinking tumors in patients with triple negative breast cancer and HR+/HER2- metastatic breast cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as balstilimab or pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ivermectin may help block the formation of growths that may become cancer. G

Trial Details

NCT ID

NCT05318469

Phase

PHASE1 / PHASE2

Sponsor

Yuan Yuan

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

• Ivermectin
• Balstilmab
• Pembrolizumab

Locations (sample)

• Los Angeles, California, United States|34.05223,-118.24368

Key Eligibility Criteria

• Age: ≥ 18 years
• Eastern Cooperative Oncology Group (ECOG) ≤ 1
• Life expectancy \> 3 months
• At least one biopsy proven Triple Negative Breast Cancer (TNBC) or HR+/HER2- breast cancer in the metastatic setting. TNBC is defined by ER and PR …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →